Acceleron ACE-083 Phase II FSHD Trial 2016

Acceleron hosted an investor webinar on October 28, 2016, presenting data on its ACE-083 Phase II trial for facioscapulohumeral dystrophy (FSHD). The presentation covered FSHD disease overview, ACE-083 program progress, and the Phase 2 trial design, featuring remarks from company executives and medical specialists.